Roth Capital Comments on Enovis' Q3 Earnings (NYSE:ENOV)

Key Points

• Roth Capital has lowered its earnings per share estimate for Enovis for Q3 2025 from $0.69 to $0.66, with a full-year estimate of $2.79 per share.
• Multiple analysts have adjusted their price targets for Enovis, with Needham & Company lowering its target from $57.00 to $49.00, reflecting a more cautious outlook on the stock's performance.
• Enovis reported earnings of $0.79 per share for the last quarter, exceeding expectations, and showed a year-over-year revenue increase of 7.5%, totaling $564.5 million.

Enovis Corporation (NYSE:ENOV - Free Report) - Investment analysts at Roth Capital reduced their Q3 2025 earnings per share (EPS) estimates for shares of Enovis in a note issued to investors on Thursday, August 7th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $0.66 per share for the quarter, down from their previous forecast of $0.69. The consensus estimate for Enovis' current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis' Q2 2026 earnings at $0.81 EPS.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.05. The business had revenue of $564.50 million during the quarter, compared to analysts' expectations of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. The business's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.62 EPS.

A number of other equities research analysts have also recently weighed in on the company. Evercore ISI lowered their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. JMP Securities lowered their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. UBS Group lowered their target price on Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Needham & Company LLC decreased their price objective on Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, Wells Fargo & Company decreased their price objective on Enovis from $48.00 to $41.00 and set an "overweight" rating on the stock in a report on Friday, August 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Enovis presently has an average rating of "Buy" and a consensus price target of $51.00.

Enovis Stock Performance

ENOV traded up $1.02 on Monday, hitting $29.77. 844,423 shares of the company traded hands, compared to its average volume of 1,200,074. The stock has a market capitalization of $1.70 billion, a PE ratio of -2.09 and a beta of 1.70. The company has a 50 day moving average of $30.47 and a 200-day moving average of $34.96. Enovis has a 12-month low of $25.47 and a 12-month high of $49.83. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Hedge Funds Weigh In On Enovis

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC boosted its position in shares of Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Enovis by 266.7% in the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock valued at $27,000 after buying an additional 536 shares in the last quarter. Quarry LP raised its stake in Enovis by 506.1% during the 4th quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after purchasing an additional 749 shares during the period. GAMMA Investing LLC raised its stake in Enovis by 144.8% during the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after purchasing an additional 692 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Enovis during the 2nd quarter valued at $46,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.